Novel Tetrafunctional Probes Identify Target Receptors and Binding Sites of Small-Molecule Drugs from Living Systems.
Animals
Binding Sites
Brain
/ metabolism
CHO Cells
Central Nervous System Agents
/ chemical synthesis
Cricetulus
Cyclohexanones
/ chemical synthesis
Hydrazines
/ chemistry
Mass Spectrometry
Mice
Molecular Probes
/ chemical synthesis
Proteomics
/ methods
Receptors, AMPA
/ analysis
Receptors, Dopamine D2
/ analysis
Receptors, GABA
/ analysis
Tetrazoles
/ chemical synthesis
Ultraviolet Rays
Journal
ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906
Informations de publication
Date de publication:
18 09 2020
18 09 2020
Historique:
pubmed:
14
8
2020
medline:
9
6
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Significant advancement of chemoproteomics has contributed to uncovering the mechanism of action (MoA) of small-molecule drugs by characterizing drug-protein interactions in living systems. However, cell-membrane proteins such as G protein-coupled receptors (GPCRs) and ion channels, due to their low abundance and unique biophysical properties associated with multiple transmembrane domains, can present challenges for proteome-wide mapping of drug-receptor interactions. Herein, we describe the development of novel tetrafunctional probes, consisting of (1) a ligand of interest, (2) 2-aryl-5-carboxytetrazole (ACT) as a photoreactive group, (3) a hydrazine-labile cleavable linker, and (4) biotin for enrichment. In live cell labeling studies, we demonstrated that the ACT-based probe showed superior reactivity and selectivity for labeling on-target GPCR by mass spectrometry analysis compared with control probes including diazirine-based probes. By leveraging ACT-based cleavable probes, we further identified a set of representative ionotropic receptors, targeted by CNS drugs, with remarkable selectivity and precise binding site information from mouse brain slices. We anticipate that the robust chemoproteomic platform using the ACT-based cleavable probe coupled with phenotypic screening should promote identification of pharmacologically relevant target receptors of drug candidates and ultimately development of first-in-class drugs with novel MoA.
Identifiants
pubmed: 32786265
doi: 10.1021/acschembio.0c00335
doi:
Substances chimiques
Central Nervous System Agents
0
Cyclohexanones
0
Hydrazines
0
Molecular Probes
0
Receptors, AMPA
0
Receptors, Dopamine D2
0
Receptors, GABA
0
Tetrazoles
0
hydrazine
27RFH0GB4R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM